Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% |
|
-.--% | -.--% |
06-27 | CAC40: caution prevails ahead of crucial deadlines | CF |
06-27 | CAC40: consolidates solo, OAT/Bund spread widens to 81Pb | CF |
Sales 2024 * | 46.35B 49.65B 3,929B | Sales 2025 * | 49.8B 53.34B 4,222B | Capitalization | 112B 120B 9,532B |
---|---|---|---|---|---|
Net income 2024 * | 7.08B 7.59B 600B | Net income 2025 * | 8.69B 9.31B 737B | EV / Sales 2024 * | 2.58 x |
Net Debt 2024 * | 6.99B 7.49B 593B | Net Debt 2025 * | 2.37B 2.54B 201B | EV / Sales 2025 * | 2.31 x |
P/E ratio 2024 * |
16.2
x | P/E ratio 2025 * |
13
x | Employees | - |
Yield 2024 * |
4.3% | Yield 2025 * |
4.53% | Free-Float | 87.13% |
Latest transcript on Sanofi
Managers | Title | Age | Since |
---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 56 | 31/08/19 |
Madeleine Roach
COO | Chief Operating Officer | 40 | 31/12/21 |
Chief Tech/Sci/R&D Officer | 51 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Kron
BRD | Director/Board Member | 70 | 30/04/14 |
Lise Kingo
BRD | Director/Board Member | 62 | 27/04/20 |
Gilles Schnepp
BRD | Director/Board Member | 64 | 21/05/20 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+2.04% | 224B | |
+13.31% | 218B | |
+8.48% | 168B |
- Stock Market
- Equities
- SAN Stock
- SAN Stock